NuCana plc (NASDAQ:NCNA) Sees Significant Drop in Short Interest

NuCana plc (NASDAQ:NCNA) was the target of a large drop in short interest in March. As of March 15th, there was short interest totalling 8,800 shares, a drop of 49.1% from the February 28th total of 17,300 shares. Based on an average daily volume of 113,200 shares, the short-interest ratio is presently 0.1 days. Approximately 0.2% of the company’s stock are sold short.

Institutional Investors Weigh In On NuCana

A number of large investors have recently added to or reduced their stakes in the stock. Schonfeld Strategic Advisors LLC bought a new position in shares of NuCana during the 4th quarter valued at $54,000. Virtu Financial LLC purchased a new stake in NuCana in the fourth quarter worth about $48,000. Citadel Advisors LLC bought a new position in shares of NuCana in the fourth quarter worth about $30,000. Finally, Two Sigma Securities LLC purchased a new position in shares of NuCana during the 4th quarter valued at about $25,000. Institutional investors own 44.00% of the company’s stock.

NuCana Stock Performance

Shares of NASDAQ:NCNA traded up $0.21 during midday trading on Friday, reaching $1.28. 546,725 shares of the company’s stock traded hands, compared to its average volume of 427,030. NuCana has a one year low of $0.69 and a one year high of $10.79. The stock has a 50 day moving average of $0.96 and a 200 day moving average of $1.47. The company has a market cap of $3.38 million, a price-to-earnings ratio of -0.12 and a beta of 0.89.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.43) by $2.11. Sell-side analysts predict that NuCana will post -13.42 EPS for the current fiscal year.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.